Novel Peptide Shows Promise for a Broad
Spectrum of Inflammation-Related Disorders
Neurology Reviews. 2015 October;23(10):27.
A peptide derived from erythropoietin (EPO) demonstrated potent clinical benefits in animal models of multiple sclerosis (MS) without inducing hematologic side effects, according to research published online ahead of print August 14 in Neurotherapeutics. The peptide, JM-4, reduced disability and protected against demyelination in mice with experimental autoimmune encephalomyelitis (EAE). Unlike full-length EPO, JM-4 did not elevate hematocrit ...